The global Viral Vector Manufacturing CDMO Services market was valued at US$ 832 million in 2025 and is anticipated to reach US$ 3587 million by 2032, at a CAGR of 23.5% from 2026 to 2032.

Viral Vector Manufacturing CDMO Services Market

Viral Vector Manufacturing CDMO Services refer to providing professional viral vector production and development services to biopharmaceutical companies. These viral vectors are usually used in gene therapy, vaccine development, cell therapy and other fields. CDMO organizations are responsible for the design and optimization of viral vectors to large-scale production in accordance with GMP standards, ensuring the safety and effectiveness of the products, while strictly controlling the quality of each production link. These services provide key technical support for biopharmaceutical companies to help accelerate the development and commercialization of their products.

The Viral Vector Manufacturing CDMO Services market has emerged as a critical enabler of the rapidly growing gene therapy and advanced biologics sector, driven by the increasing demand for specialized production capabilities and accelerated time-to-market for innovative therapies. The market is characterized by high technological barriers, requiring expertise in viral vector design, process development, cGMP-compliant manufacturing, and quality assurance. Companies in this space are leveraging advanced bioprocessing technologies, automation, and artificial intelligence tools to improve yield, consistency, and scalability while maintaining regulatory compliance. Strategic partnerships between biotechnology firms and CDMOs are becoming increasingly common, allowing developers to outsource complex manufacturing tasks and focus on clinical development and commercialization. Overall, the market is marked by intense competition among specialized service providers, rapid technological innovation, and growing adoption of viral vector-based therapies across diverse therapeutic areas, positioning CDMOs as indispensable partners in the biopharmaceutical value chain.

This report delivers a comprehensive overview of the global Viral Vector Manufacturing CDMO Services market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Viral Vector Manufacturing CDMO Services. The Viral Vector Manufacturing CDMO Services market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Viral Vector Manufacturing CDMO Services market comprehensively. Regional market sizes by Type, by Application, by Development Scope, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Viral Vector Manufacturing CDMO Services manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Viral Vector Manufacturing CDMO Services Market Report

Report Metric	Details
Report Name	Viral Vector Manufacturing CDMO Services Market
Accounted market size in 2025	US$ 832 million
Forecasted market size in 2032	US$ 3587 million
CAGR	23.5%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Adeno-associated Virus Lentivirus Adenovirus HSV Others
Segment by Development Scope	Clinical stage CDMOs Commercial stage CDMOs End to end lifecycle CDMOs
Segment by Manufacturing Technology	Adherent Cell Based Suspension Based
Segment by Application	Vaccine Development Gene Therapy Academic Scientific Research Institution Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), CCRM, FUJIFILM Diosynth Biotechnologies, Biovian, Miltenyi Bioindustry, Aldevron, Takara Bio, Yposkesi, Genezen, Exthera, Flash Therapeutics, VIVEBiotech, FinVector, uBriGene, Eurogentec, VGXI, GenScript ProBio, EurekaBio, Obio Technology, GeneSail Biotech, VectorBuilder, WuXi ATU, Ubrigene, Porton Biologics, Pharmaron, PackGene Biotechnology, Hillgene, Asymchem
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Development Scope, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Viral Vector Manufacturing CDMO Services companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Viral Vector Manufacturing CDMO Services Market growing?

Ans: The Viral Vector Manufacturing CDMO Services Market witnessing a CAGR of 23.5% during the forecast period 2026-2032.

What is the Viral Vector Manufacturing CDMO Services Market size in 2032?

Ans: The Viral Vector Manufacturing CDMO Services Market size in 2032 will be US$ 3587 million.

Who are the main players in the Viral Vector Manufacturing CDMO Services Market report?

Ans: The main players in the Viral Vector Manufacturing CDMO Services Market are Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), CCRM, FUJIFILM Diosynth Biotechnologies, Biovian, Miltenyi Bioindustry, Aldevron, Takara Bio, Yposkesi, Genezen, Exthera, Flash Therapeutics, VIVEBiotech, FinVector, uBriGene, Eurogentec, VGXI, GenScript ProBio, EurekaBio, Obio Technology, GeneSail Biotech, VectorBuilder, WuXi ATU, Ubrigene, Porton Biologics, Pharmaron, PackGene Biotechnology, Hillgene, Asymchem

What are the Application segmentation covered in the Viral Vector Manufacturing CDMO Services Market report?

Ans: The Applications covered in the Viral Vector Manufacturing CDMO Services Market report are Vaccine Development, Gene Therapy, Academic Scientific Research Institution, Others

What are the Type segmentation covered in the Viral Vector Manufacturing CDMO Services Market report?

Ans: The Types covered in the Viral Vector Manufacturing CDMO Services Market report are Adeno-associated Virus, Lentivirus, Adenovirus, HSV, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Adeno-associated Virus

1.2.3 Lentivirus

1.2.4 Adenovirus

1.2.5 HSV

1.2.6 Others

1.3 Market by Development Scope

1.3.1 Global Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Development Scope: 2021 vs 2025 vs 2032

1.3.2 Clinical stage CDMOs

1.3.3 Commercial stage CDMOs

1.3.4 End to end lifecycle CDMOs

1.4 Market by Manufacturing Technology

1.4.1 Global Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Manufacturing Technology: 2021 vs 2025 vs 2032

1.4.2 Adherent Cell Based

1.4.3 Suspension Based

1.5 Market by Application

1.5.1 Global Viral Vector Manufacturing CDMO Services Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Vaccine Development

1.5.3 Gene Therapy

1.5.4 Academic Scientific Research Institution

1.5.5 Others

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Viral Vector Manufacturing CDMO Services Market Perspective (2021–2032)

2.2 Global Viral Vector Manufacturing CDMO Services Growth Trends by Region

2.2.1 Global Viral Vector Manufacturing CDMO Services Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Viral Vector Manufacturing CDMO Services Historic Market Size by Region (2021–2026)

2.2.3 Viral Vector Manufacturing CDMO Services Forecasted Market Size by Region (2027–2032)

2.3 Viral Vector Manufacturing CDMO Services Market Dynamics

2.3.1 Viral Vector Manufacturing CDMO Services Industry Trends

2.3.2 Viral Vector Manufacturing CDMO Services Market Drivers

2.3.3 Viral Vector Manufacturing CDMO Services Market Challenges

2.3.4 Viral Vector Manufacturing CDMO Services Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Viral Vector Manufacturing CDMO Services Players by Revenue

3.1.1 Global Top Viral Vector Manufacturing CDMO Services Players by Revenue (2021–2026)

3.1.2 Global Viral Vector Manufacturing CDMO Services Revenue Market Share by Players (2021–2026)

3.2 Global Top Viral Vector Manufacturing CDMO Services Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Viral Vector Manufacturing CDMO Services Revenue

3.4 Global Viral Vector Manufacturing CDMO Services Market Concentration Ratio

3.4.1 Global Viral Vector Manufacturing CDMO Services Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Viral Vector Manufacturing CDMO Services Revenue in 2025

3.5 Global Key Players of Viral Vector Manufacturing CDMO Services Head Offices and Areas Served

3.6 Global Key Players of Viral Vector Manufacturing CDMO Services, Products and Applications

3.7 Global Key Players of Viral Vector Manufacturing CDMO Services, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Viral Vector Manufacturing CDMO Services Breakdown Data by Type

4.1 Global Viral Vector Manufacturing CDMO Services Historic Market Size by Type (2021–2026)

4.2 Global Viral Vector Manufacturing CDMO Services Forecasted Market Size by Type (2027–2032)

5 Viral Vector Manufacturing CDMO Services Breakdown Data by Application

5.1 Global Viral Vector Manufacturing CDMO Services Historic Market Size by Application (2021–2026)

5.2 Global Viral Vector Manufacturing CDMO Services Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Viral Vector Manufacturing CDMO Services Market Size (2021–2032)

6.2 North America Viral Vector Manufacturing CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Viral Vector Manufacturing CDMO Services Market Size by Country (2021–2026)

6.4 North America Viral Vector Manufacturing CDMO Services Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Viral Vector Manufacturing CDMO Services Market Size (2021–2032)

7.2 Europe Viral Vector Manufacturing CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Viral Vector Manufacturing CDMO Services Market Size by Country (2021–2026)

7.4 Europe Viral Vector Manufacturing CDMO Services Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size (2021–2032)

8.2 Asia-Pacific Viral Vector Manufacturing CDMO Services Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size by Region (2021–2026)

8.4 Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Viral Vector Manufacturing CDMO Services Market Size (2021–2032)

9.2 Latin America Viral Vector Manufacturing CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Viral Vector Manufacturing CDMO Services Market Size by Country (2021–2026)

9.4 Latin America Viral Vector Manufacturing CDMO Services Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size (2021–2032)

10.2 Middle East & Africa Viral Vector Manufacturing CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size by Country (2021–2026)

10.4 Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Thermo Fisher Scientific

11.1.1 Thermo Fisher Scientific Company Details

11.1.2 Thermo Fisher Scientific Business Overview

11.1.3 Thermo Fisher Scientific Viral Vector Manufacturing CDMO Services Introduction

11.1.4 Thermo Fisher Scientific Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.1.5 Thermo Fisher Scientific Recent Development

11.2 Lonza

11.2.1 Lonza Company Details

11.2.2 Lonza Business Overview

11.2.3 Lonza Viral Vector Manufacturing CDMO Services Introduction

11.2.4 Lonza Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.2.5 Lonza Recent Development

11.3 Catalent

11.3.1 Catalent Company Details

11.3.2 Catalent Business Overview

11.3.3 Catalent Viral Vector Manufacturing CDMO Services Introduction

11.3.4 Catalent Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.3.5 Catalent Recent Development

11.4 Charles River

11.4.1 Charles River Company Details

11.4.2 Charles River Business Overview

11.4.3 Charles River Viral Vector Manufacturing CDMO Services Introduction

11.4.4 Charles River Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.4.5 Charles River Recent Development

11.5 Merck

11.5.1 Merck Company Details

11.5.2 Merck Business Overview

11.5.3 Merck Viral Vector Manufacturing CDMO Services Introduction

11.5.4 Merck Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.5.5 Merck Recent Development

11.6 SK pharmteco

11.6.1 SK pharmteco Company Details

11.6.2 SK pharmteco Business Overview

11.6.3 SK pharmteco Viral Vector Manufacturing CDMO Services Introduction

11.6.4 SK pharmteco Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.6.5 SK pharmteco Recent Development

11.7 Oxford Biomedica

11.7.1 Oxford Biomedica Company Details

11.7.2 Oxford Biomedica Business Overview

11.7.3 Oxford Biomedica Viral Vector Manufacturing CDMO Services Introduction

11.7.4 Oxford Biomedica Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.7.5 Oxford Biomedica Recent Development

11.8 AGC Biologics（MolMed）

11.8.1 AGC Biologics（MolMed） Company Details

11.8.2 AGC Biologics（MolMed） Business Overview

11.8.3 AGC Biologics（MolMed） Viral Vector Manufacturing CDMO Services Introduction

11.8.4 AGC Biologics（MolMed） Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.8.5 AGC Biologics（MolMed） Recent Development

11.9 Gene Universal

11.9.1 Gene Universal Company Details

11.9.2 Gene Universal Business Overview

11.9.3 Gene Universal Viral Vector Manufacturing CDMO Services Introduction

11.9.4 Gene Universal Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.9.5 Gene Universal Recent Development

11.10 Polyplus (Sartorius)

11.10.1 Polyplus (Sartorius) Company Details

11.10.2 Polyplus (Sartorius) Business Overview

11.10.3 Polyplus (Sartorius) Viral Vector Manufacturing CDMO Services Introduction

11.10.4 Polyplus (Sartorius) Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.10.5 Polyplus (Sartorius) Recent Development

11.11 CCRM

11.11.1 CCRM Company Details

11.11.2 CCRM Business Overview

11.11.3 CCRM Viral Vector Manufacturing CDMO Services Introduction

11.11.4 CCRM Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.11.5 CCRM Recent Development

11.12 FUJIFILM Diosynth Biotechnologies

11.12.1 FUJIFILM Diosynth Biotechnologies Company Details

11.12.2 FUJIFILM Diosynth Biotechnologies Business Overview

11.12.3 FUJIFILM Diosynth Biotechnologies Viral Vector Manufacturing CDMO Services Introduction

11.12.4 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.12.5 FUJIFILM Diosynth Biotechnologies Recent Development

11.13 Biovian

11.13.1 Biovian Company Details

11.13.2 Biovian Business Overview

11.13.3 Biovian Viral Vector Manufacturing CDMO Services Introduction

11.13.4 Biovian Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.13.5 Biovian Recent Development

11.14 Miltenyi Bioindustry

11.14.1 Miltenyi Bioindustry Company Details

11.14.2 Miltenyi Bioindustry Business Overview

11.14.3 Miltenyi Bioindustry Viral Vector Manufacturing CDMO Services Introduction

11.14.4 Miltenyi Bioindustry Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.14.5 Miltenyi Bioindustry Recent Development

11.15 Aldevron

11.15.1 Aldevron Company Details

11.15.2 Aldevron Business Overview

11.15.3 Aldevron Viral Vector Manufacturing CDMO Services Introduction

11.15.4 Aldevron Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.15.5 Aldevron Recent Development

11.16 Takara Bio

11.16.1 Takara Bio Company Details

11.16.2 Takara Bio Business Overview

11.16.3 Takara Bio Viral Vector Manufacturing CDMO Services Introduction

11.16.4 Takara Bio Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.16.5 Takara Bio Recent Development

11.17 Yposkesi

11.17.1 Yposkesi Company Details

11.17.2 Yposkesi Business Overview

11.17.3 Yposkesi Viral Vector Manufacturing CDMO Services Introduction

11.17.4 Yposkesi Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.17.5 Yposkesi Recent Development

11.18 Genezen

11.18.1 Genezen Company Details

11.18.2 Genezen Business Overview

11.18.3 Genezen Viral Vector Manufacturing CDMO Services Introduction

11.18.4 Genezen Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.18.5 Genezen Recent Development

11.19 Exthera

11.19.1 Exthera Company Details

11.19.2 Exthera Business Overview

11.19.3 Exthera Viral Vector Manufacturing CDMO Services Introduction

11.19.4 Exthera Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.19.5 Exthera Recent Development

11.20 Flash Therapeutics

11.20.1 Flash Therapeutics Company Details

11.20.2 Flash Therapeutics Business Overview

11.20.3 Flash Therapeutics Viral Vector Manufacturing CDMO Services Introduction

11.20.4 Flash Therapeutics Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.20.5 Flash Therapeutics Recent Development

11.21 VIVEBiotech

11.21.1 VIVEBiotech Company Details

11.21.2 VIVEBiotech Business Overview

11.21.3 VIVEBiotech Viral Vector Manufacturing CDMO Services Introduction

11.21.4 VIVEBiotech Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.21.5 VIVEBiotech Recent Development

11.22 FinVector

11.22.1 FinVector Company Details

11.22.2 FinVector Business Overview

11.22.3 FinVector Viral Vector Manufacturing CDMO Services Introduction

11.22.4 FinVector Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.22.5 FinVector Recent Development

11.23 uBriGene

11.23.1 uBriGene Company Details

11.23.2 uBriGene Business Overview

11.23.3 uBriGene Viral Vector Manufacturing CDMO Services Introduction

11.23.4 uBriGene Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.23.5 uBriGene Recent Development

11.24 Eurogentec

11.24.1 Eurogentec Company Details

11.24.2 Eurogentec Business Overview

11.24.3 Eurogentec Viral Vector Manufacturing CDMO Services Introduction

11.24.4 Eurogentec Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.24.5 Eurogentec Recent Development

11.25 VGXI

11.25.1 VGXI Company Details

11.25.2 VGXI Business Overview

11.25.3 VGXI Viral Vector Manufacturing CDMO Services Introduction

11.25.4 VGXI Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.25.5 VGXI Recent Development

11.26 GenScript ProBio

11.26.1 GenScript ProBio Company Details

11.26.2 GenScript ProBio Business Overview

11.26.3 GenScript ProBio Viral Vector Manufacturing CDMO Services Introduction

11.26.4 GenScript ProBio Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.26.5 GenScript ProBio Recent Development

11.27 EurekaBio

11.27.1 EurekaBio Company Details

11.27.2 EurekaBio Business Overview

11.27.3 EurekaBio Viral Vector Manufacturing CDMO Services Introduction

11.27.4 EurekaBio Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.27.5 EurekaBio Recent Development

11.28 Obio Technology

11.28.1 Obio Technology Company Details

11.28.2 Obio Technology Business Overview

11.28.3 Obio Technology Viral Vector Manufacturing CDMO Services Introduction

11.28.4 Obio Technology Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.28.5 Obio Technology Recent Development

11.29 GeneSail Biotech

11.29.1 GeneSail Biotech Company Details

11.29.2 GeneSail Biotech Business Overview

11.29.3 GeneSail Biotech Viral Vector Manufacturing CDMO Services Introduction

11.29.4 GeneSail Biotech Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.29.5 GeneSail Biotech Recent Development

11.30 VectorBuilder

11.30.1 VectorBuilder Company Details

11.30.2 VectorBuilder Business Overview

11.30.3 VectorBuilder Viral Vector Manufacturing CDMO Services Introduction

11.30.4 VectorBuilder Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.30.5 VectorBuilder Recent Development

11.31 WuXi ATU

11.31.1 WuXi ATU Company Details

11.31.2 WuXi ATU Business Overview

11.31.3 WuXi ATU Viral Vector Manufacturing CDMO Services Introduction

11.31.4 WuXi ATU Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.31.5 WuXi ATU Recent Development

11.32 Ubrigene

11.32.1 Ubrigene Company Details

11.32.2 Ubrigene Business Overview

11.32.3 Ubrigene Viral Vector Manufacturing CDMO Services Introduction

11.32.4 Ubrigene Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.32.5 Ubrigene Recent Development

11.33 Porton Biologics

11.33.1 Porton Biologics Company Details

11.33.2 Porton Biologics Business Overview

11.33.3 Porton Biologics Viral Vector Manufacturing CDMO Services Introduction

11.33.4 Porton Biologics Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.33.5 Porton Biologics Recent Development

11.34 Pharmaron

11.34.1 Pharmaron Company Details

11.34.2 Pharmaron Business Overview

11.34.3 Pharmaron Viral Vector Manufacturing CDMO Services Introduction

11.34.4 Pharmaron Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.34.5 Pharmaron Recent Development

11.35 PackGene Biotechnology

11.35.1 PackGene Biotechnology Company Details

11.35.2 PackGene Biotechnology Business Overview

11.35.3 PackGene Biotechnology Viral Vector Manufacturing CDMO Services Introduction

11.35.4 PackGene Biotechnology Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.35.5 PackGene Biotechnology Recent Development

11.36 Hillgene

11.36.1 Hillgene Company Details

11.36.2 Hillgene Business Overview

11.36.3 Hillgene Viral Vector Manufacturing CDMO Services Introduction

11.36.4 Hillgene Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.36.5 Hillgene Recent Development

11.37 Asymchem

11.37.1 Asymchem Company Details

11.37.2 Asymchem Business Overview

11.37.3 Asymchem Viral Vector Manufacturing CDMO Services Introduction

11.37.4 Asymchem Revenue in Viral Vector Manufacturing CDMO Services Business (2021–2026)

11.37.5 Asymchem Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Lonza

Biovian

Genezen

Pharmaron

FinVector

FUJIFILM Diosynth Biotechnologies

Thermo Fisher Scientific

AGC Biologics（MolMed）

PackGene Biotechnology

Hillgene

Asymchem

List of Tables

Table 1. Global Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Adeno-associated Virus

Table 3. Key Players of Lentivirus

Table 4. Key Players of Adenovirus

Table 5. Key Players of HSV

Table 6. Key Players of Others

Table 7. Global Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Development Scope (US$ Million): 2021 vs 2025 vs 2032

Table 8. Key Players of Clinical stage CDMOs

Table 9. Key Players of Commercial stage CDMOs

Table 10. Key Players of End to end lifecycle CDMOs

Table 11. Global Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Manufacturing Technology (US$ Million): 2021 vs 2025 vs 2032

Table 12. Key Players of Adherent Cell Based

Table 13. Key Players of Suspension Based

Table 14. Global Viral Vector Manufacturing CDMO Services Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 15. Global Viral Vector Manufacturing CDMO Services Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 16. Global Viral Vector Manufacturing CDMO Services Market Size by Region (US$ Million), 2021–2026

Table 17. Global Viral Vector Manufacturing CDMO Services Market Share by Region (2021–2026)

Table 18. Global Viral Vector Manufacturing CDMO Services Forecasted Market Size by Region (US$ Million), 2027–2032

Table 19. Global Viral Vector Manufacturing CDMO Services Market Share by Region (2027–2032)

Table 20. Viral Vector Manufacturing CDMO Services Market Trends

Table 21. Viral Vector Manufacturing CDMO Services Market Drivers

Table 22. Viral Vector Manufacturing CDMO Services Market Challenges

Table 23. Viral Vector Manufacturing CDMO Services Market Restraints

Table 24. Global Viral Vector Manufacturing CDMO Services Revenue by Players (US$ Million), 2021–2026

Table 25. Global Viral Vector Manufacturing CDMO Services Market Share by Players (2021–2026)

Table 26. Global Top Viral Vector Manufacturing CDMO Services Players by Tier (Tier 1, Tier 2, and Tier 3), based on Viral Vector Manufacturing CDMO Services Revenue, 2025

Table 27. Ranking of Global Top Viral Vector Manufacturing CDMO Services Companies by Revenue (US$ Million) in 2025

Table 28. Global 5 Largest Players Market Share by Viral Vector Manufacturing CDMO Services Revenue (CR5 and HHI), 2021–2026

Table 29. Global Key Players of Viral Vector Manufacturing CDMO Services, Headquarters and Area Served

Table 30. Global Key Players of Viral Vector Manufacturing CDMO Services, Products and Applications

Table 31. Global Key Players of Viral Vector Manufacturing CDMO Services, Date of General Availability (GA)

Table 32. Mergers and Acquisitions, Expansion Plans

Table 33. Global Viral Vector Manufacturing CDMO Services Market Size by Type (US$ Million), 2021–2026

Table 34. Global Viral Vector Manufacturing CDMO Services Revenue Market Share by Type (2021–2026)

Table 35. Global Viral Vector Manufacturing CDMO Services Forecasted Market Size by Type (US$ Million), 2027–2032

Table 36. Global Viral Vector Manufacturing CDMO Services Revenue Market Share by Type (2027–2032)

Table 37. Global Viral Vector Manufacturing CDMO Services Market Size by Application (US$ Million), 2021–2026

Table 38. Global Viral Vector Manufacturing CDMO Services Revenue Market Share by Application (2021–2026)

Table 39. Global Viral Vector Manufacturing CDMO Services Forecasted Market Size by Application (US$ Million), 2027–2032

Table 40. Global Viral Vector Manufacturing CDMO Services Revenue Market Share by Application (2027–2032)

Table 41. North America Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 42. North America Viral Vector Manufacturing CDMO Services Market Size by Country (US$ Million), 2021–2026

Table 43. North America Viral Vector Manufacturing CDMO Services Market Size by Country (US$ Million), 2027–2032

Table 44. Europe Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Europe Viral Vector Manufacturing CDMO Services Market Size by Country (US$ Million), 2021–2026

Table 46. Europe Viral Vector Manufacturing CDMO Services Market Size by Country (US$ Million), 2027–2032

Table 47. Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 48. Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size by Region (US$ Million), 2021–2026

Table 49. Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size by Region (US$ Million), 2027–2032

Table 50. Latin America Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 51. Latin America Viral Vector Manufacturing CDMO Services Market Size by Country (US$ Million), 2021–2026

Table 52. Latin America Viral Vector Manufacturing CDMO Services Market Size by Country (US$ Million), 2027–2032

Table 53. Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 54. Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size by Country (US$ Million), 2021–2026

Table 55. Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size by Country (US$ Million), 2027–2032

Table 56. Thermo Fisher Scientific Company Details

Table 57. Thermo Fisher Scientific Business Overview

Table 58. Thermo Fisher Scientific Viral Vector Manufacturing CDMO Services Product

Table 59. Thermo Fisher Scientific Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 60. Thermo Fisher Scientific Recent Development

Table 61. Lonza Company Details

Table 62. Lonza Business Overview

Table 63. Lonza Viral Vector Manufacturing CDMO Services Product

Table 64. Lonza Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 65. Lonza Recent Development

Table 66. Catalent Company Details

Table 67. Catalent Business Overview

Table 68. Catalent Viral Vector Manufacturing CDMO Services Product

Table 69. Catalent Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 70. Catalent Recent Development

Table 71. Charles River Company Details

Table 72. Charles River Business Overview

Table 73. Charles River Viral Vector Manufacturing CDMO Services Product

Table 74. Charles River Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 75. Charles River Recent Development

Table 76. Merck Company Details

Table 77. Merck Business Overview

Table 78. Merck Viral Vector Manufacturing CDMO Services Product

Table 79. Merck Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 80. Merck Recent Development

Table 81. SK pharmteco Company Details

Table 82. SK pharmteco Business Overview

Table 83. SK pharmteco Viral Vector Manufacturing CDMO Services Product

Table 84. SK pharmteco Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 85. SK pharmteco Recent Development

Table 86. Oxford Biomedica Company Details

Table 87. Oxford Biomedica Business Overview

Table 88. Oxford Biomedica Viral Vector Manufacturing CDMO Services Product

Table 89. Oxford Biomedica Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 90. Oxford Biomedica Recent Development

Table 91. AGC Biologics（MolMed） Company Details

Table 92. AGC Biologics（MolMed） Business Overview

Table 93. AGC Biologics（MolMed） Viral Vector Manufacturing CDMO Services Product

Table 94. AGC Biologics（MolMed） Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 95. AGC Biologics（MolMed） Recent Development

Table 96. Gene Universal Company Details

Table 97. Gene Universal Business Overview

Table 98. Gene Universal Viral Vector Manufacturing CDMO Services Product

Table 99. Gene Universal Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 100. Gene Universal Recent Development

Table 101. Polyplus (Sartorius) Company Details

Table 102. Polyplus (Sartorius) Business Overview

Table 103. Polyplus (Sartorius) Viral Vector Manufacturing CDMO Services Product

Table 104. Polyplus (Sartorius) Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 105. Polyplus (Sartorius) Recent Development

Table 106. CCRM Company Details

Table 107. CCRM Business Overview

Table 108. CCRM Viral Vector Manufacturing CDMO Services Product

Table 109. CCRM Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 110. CCRM Recent Development

Table 111. FUJIFILM Diosynth Biotechnologies Company Details

Table 112. FUJIFILM Diosynth Biotechnologies Business Overview

Table 113. FUJIFILM Diosynth Biotechnologies Viral Vector Manufacturing CDMO Services Product

Table 114. FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 115. FUJIFILM Diosynth Biotechnologies Recent Development

Table 116. Biovian Company Details

Table 117. Biovian Business Overview

Table 118. Biovian Viral Vector Manufacturing CDMO Services Product

Table 119. Biovian Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 120. Biovian Recent Development

Table 121. Miltenyi Bioindustry Company Details

Table 122. Miltenyi Bioindustry Business Overview

Table 123. Miltenyi Bioindustry Viral Vector Manufacturing CDMO Services Product

Table 124. Miltenyi Bioindustry Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 125. Miltenyi Bioindustry Recent Development

Table 126. Aldevron Company Details

Table 127. Aldevron Business Overview

Table 128. Aldevron Viral Vector Manufacturing CDMO Services Product

Table 129. Aldevron Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 130. Aldevron Recent Development

Table 131. Takara Bio Company Details

Table 132. Takara Bio Business Overview

Table 133. Takara Bio Viral Vector Manufacturing CDMO Services Product

Table 134. Takara Bio Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 135. Takara Bio Recent Development

Table 136. Yposkesi Company Details

Table 137. Yposkesi Business Overview

Table 138. Yposkesi Viral Vector Manufacturing CDMO Services Product

Table 139. Yposkesi Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 140. Yposkesi Recent Development

Table 141. Genezen Company Details

Table 142. Genezen Business Overview

Table 143. Genezen Viral Vector Manufacturing CDMO Services Product

Table 144. Genezen Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 145. Genezen Recent Development

Table 146. Exthera Company Details

Table 147. Exthera Business Overview

Table 148. Exthera Viral Vector Manufacturing CDMO Services Product

Table 149. Exthera Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 150. Exthera Recent Development

Table 151. Flash Therapeutics Company Details

Table 152. Flash Therapeutics Business Overview

Table 153. Flash Therapeutics Viral Vector Manufacturing CDMO Services Product

Table 154. Flash Therapeutics Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 155. Flash Therapeutics Recent Development

Table 156. VIVEBiotech Company Details

Table 157. VIVEBiotech Business Overview

Table 158. VIVEBiotech Viral Vector Manufacturing CDMO Services Product

Table 159. VIVEBiotech Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 160. VIVEBiotech Recent Development

Table 161. FinVector Company Details

Table 162. FinVector Business Overview

Table 163. FinVector Viral Vector Manufacturing CDMO Services Product

Table 164. FinVector Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 165. FinVector Recent Development

Table 166. uBriGene Company Details

Table 167. uBriGene Business Overview

Table 168. uBriGene Viral Vector Manufacturing CDMO Services Product

Table 169. uBriGene Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 170. uBriGene Recent Development

Table 171. Eurogentec Company Details

Table 172. Eurogentec Business Overview

Table 173. Eurogentec Viral Vector Manufacturing CDMO Services Product

Table 174. Eurogentec Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 175. Eurogentec Recent Development

Table 176. VGXI Company Details

Table 177. VGXI Business Overview

Table 178. VGXI Viral Vector Manufacturing CDMO Services Product

Table 179. VGXI Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 180. VGXI Recent Development

Table 181. GenScript ProBio Company Details

Table 182. GenScript ProBio Business Overview

Table 183. GenScript ProBio Viral Vector Manufacturing CDMO Services Product

Table 184. GenScript ProBio Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 185. GenScript ProBio Recent Development

Table 186. EurekaBio Company Details

Table 187. EurekaBio Business Overview

Table 188. EurekaBio Viral Vector Manufacturing CDMO Services Product

Table 189. EurekaBio Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 190. EurekaBio Recent Development

Table 191. Obio Technology Company Details

Table 192. Obio Technology Business Overview

Table 193. Obio Technology Viral Vector Manufacturing CDMO Services Product

Table 194. Obio Technology Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 195. Obio Technology Recent Development

Table 196. GeneSail Biotech Company Details

Table 197. GeneSail Biotech Business Overview

Table 198. GeneSail Biotech Viral Vector Manufacturing CDMO Services Product

Table 199. GeneSail Biotech Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 200. GeneSail Biotech Recent Development

Table 201. VectorBuilder Company Details

Table 202. VectorBuilder Business Overview

Table 203. VectorBuilder Viral Vector Manufacturing CDMO Services Product

Table 204. VectorBuilder Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 205. VectorBuilder Recent Development

Table 206. WuXi ATU Company Details

Table 207. WuXi ATU Business Overview

Table 208. WuXi ATU Viral Vector Manufacturing CDMO Services Product

Table 209. WuXi ATU Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 210. WuXi ATU Recent Development

Table 211. Ubrigene Company Details

Table 212. Ubrigene Business Overview

Table 213. Ubrigene Viral Vector Manufacturing CDMO Services Product

Table 214. Ubrigene Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 215. Ubrigene Recent Development

Table 216. Porton Biologics Company Details

Table 217. Porton Biologics Business Overview

Table 218. Porton Biologics Viral Vector Manufacturing CDMO Services Product

Table 219. Porton Biologics Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 220. Porton Biologics Recent Development

Table 221. Pharmaron Company Details

Table 222. Pharmaron Business Overview

Table 223. Pharmaron Viral Vector Manufacturing CDMO Services Product

Table 224. Pharmaron Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 225. Pharmaron Recent Development

Table 226. PackGene Biotechnology Company Details

Table 227. PackGene Biotechnology Business Overview

Table 228. PackGene Biotechnology Viral Vector Manufacturing CDMO Services Product

Table 229. PackGene Biotechnology Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 230. PackGene Biotechnology Recent Development

Table 231. Hillgene Company Details

Table 232. Hillgene Business Overview

Table 233. Hillgene Viral Vector Manufacturing CDMO Services Product

Table 234. Hillgene Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 235. Hillgene Recent Development

Table 236. Asymchem Company Details

Table 237. Asymchem Business Overview

Table 238. Asymchem Viral Vector Manufacturing CDMO Services Product

Table 239. Asymchem Revenue in Viral Vector Manufacturing CDMO Services Business (US$ Million), 2021–2026

Table 240. Asymchem Recent Development

Table 241. Research Programs/Design for This Report

Table 242. Key Data Information from Secondary Sources

Table 243. Key Data Information from Primary Sources

Table 244. Authors List of This Report

List of Figures

Figure 1. Viral Vector Manufacturing CDMO Services Picture

Figure 2. Global Viral Vector Manufacturing CDMO Services Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Viral Vector Manufacturing CDMO Services Market Share by Type: 2025 vs 2032

Figure 4. Adeno-associated Virus Features

Figure 5. Lentivirus Features

Figure 6. Adenovirus Features

Figure 7. HSV Features

Figure 8. Others Features

Figure 9. Global Viral Vector Manufacturing CDMO Services Market Size Comparison by Development Scope (US$ Million), 2021–2032

Figure 10. Clinical stage CDMOs Features

Figure 11. Commercial stage CDMOs Features

Figure 12. End to end lifecycle CDMOs Features

Figure 13. Global Viral Vector Manufacturing CDMO Services Market Size Comparison by Manufacturing Technology (US$ Million), 2021–2032

Figure 14. Adherent Cell Based Features

Figure 15. Suspension Based Features

Figure 16. Global Viral Vector Manufacturing CDMO Services Market Size by Application (US$ Million), 2021–2032

Figure 17. Global Viral Vector Manufacturing CDMO Services Market Share by Application: 2025 vs 2032

Figure 18. Vaccine Development Case Studies

Figure 19. Gene Therapy Case Studies

Figure 20. Academic Scientific Research Institution Case Studies

Figure 21. Others Case Studies

Figure 22. Viral Vector Manufacturing CDMO Services Report Years Considered

Figure 23. Global Viral Vector Manufacturing CDMO Services Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 24. Global Viral Vector Manufacturing CDMO Services Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 25. Global Viral Vector Manufacturing CDMO Services Market Share by Region: 2025 vs 2032

Figure 26. Global Viral Vector Manufacturing CDMO Services Market Share by Players in 2025

Figure 27. Global Viral Vector Manufacturing CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 28. The Top 10 and 5 Players Market Share by Viral Vector Manufacturing CDMO Services Revenue in 2025

Figure 29. North America Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. North America Viral Vector Manufacturing CDMO Services Market Share by Country (2021–2032)

Figure 31. United States Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Canada Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Europe Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Europe Viral Vector Manufacturing CDMO Services Market Share by Country (2021–2032)

Figure 35. Germany Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. France Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. U.K. Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Italy Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Russia Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Ireland Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Asia-Pacific Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Asia-Pacific Viral Vector Manufacturing CDMO Services Market Share by Region (2021–2032)

Figure 43. China Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Japan Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. South Korea Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Southeast Asia Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. India Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Australia & New Zealand Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Latin America Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. Latin America Viral Vector Manufacturing CDMO Services Market Share by Country (2021–2032)

Figure 51. Mexico Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 52. Brazil Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Middle East & Africa Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 54. Middle East & Africa Viral Vector Manufacturing CDMO Services Market Share by Country (2021–2032)

Figure 55. Israel Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 56. Saudi Arabia Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 57. UAE Viral Vector Manufacturing CDMO Services Market Size YoY Growth (US$ Million), 2021–2032

Figure 58. Thermo Fisher Scientific Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 59. Lonza Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 60. Catalent Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 61. Charles River Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 62. Merck Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 63. SK pharmteco Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 64. Oxford Biomedica Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 65. AGC Biologics（MolMed） Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 66. Gene Universal Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 67. Polyplus (Sartorius) Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 68. CCRM Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 69. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 70. Biovian Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 71. Miltenyi Bioindustry Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 72. Aldevron Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 73. Takara Bio Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 74. Yposkesi Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 75. Genezen Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 76. Exthera Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 77. Flash Therapeutics Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 78. VIVEBiotech Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 79. FinVector Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 80. uBriGene Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 81. Eurogentec Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 82. VGXI Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 83. GenScript ProBio Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 84. EurekaBio Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 85. Obio Technology Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 86. GeneSail Biotech Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 87. VectorBuilder Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 88. WuXi ATU Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 89. Ubrigene Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 90. Porton Biologics Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 91. Pharmaron Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 92. PackGene Biotechnology Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 93. Hillgene Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 94. Asymchem Revenue Growth Rate in Viral Vector Manufacturing CDMO Services Business (2021–2026)

Figure 95. Bottom-up and Top-down Approaches for This Report

Figure 96. Data Triangulation

Figure 97. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global mRNA CDMO Service Market Research Report 2024

Global Adeno Associated Virus AAV Vector Production CDMO Market Research Report 2024

Global Plasmid DNA CDMO Service Market Research Report 2024

Global Biopharmaceutical CDMO Service Market Research Report 2024

Global Viral Vector Development and Manufacturing Services Market Research Report 2025

Global Biopharmaceutical CDMO Market Research Report 2025

Global Cell Therapy CDMO Services Market Research Report 2025

Global Oligonucleotide Drug CDMO Services Market Research Report 2024

Global Biopharmaceutical and Bio CDMO Market Research Report 2024

Global Pharmaceutical CDMO Market Research Report 2025

Global Full Service CDMO Market Research Report 2024

Global Viral Vector Manufacturing for Gene Therapy Market Research Report 2024

Global Biologics CDMO Services Market Research Report 2024

Global Formulation CDMO Services Market Research Report 2024

Global Antibody Drug CDMO Service Market Research Report 2024

Global Oligonucleotide CDMO Market Research Report 2025

Global Chemical CDMO Market Research Report 2024

Global Contract Dose Manufacturing Market Insights Forecast to 2030

CGT CDMO Market

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions